Group 1: Company Advantages - The company has a complete industrial chain layout, allowing it to independently produce active pharmaceutical ingredients and key excipients, ensuring product quality while effectively controlling costs [2] - A full-channel coverage system has been established, particularly in the outpatient market, which has become a new engine for revenue growth [2] - Continuous high investment in R&D to innovate and expand the product line, with a focus on strengthening the "JiuYue" brand in the transdermal drug delivery field [2] Group 2: Product Expectations and Market Strategy - The ketoprofen gel patch was approved for market in 2023 and has entered the national medical insurance directory, being the first generic product in the domestic market [3] - The company is optimistic about the market prospects for the ketoprofen gel patch and has developed new sales strategies focusing on outpatient market resources and internal sales team assessments [3] Group 3: Financial Projections - The company expects a revenue growth of 10-20% year-on-year for 2025, with a similar growth forecast for net profit excluding non-recurring items [4] - There are risks associated with achieving these targets due to market conditions, operational environment, and industry policies, which may introduce significant uncertainties [4] Group 4: Product Development Progress - The indomethacin gel patch is currently undergoing supplementary data review, while the pepper and musk gel patch has completed supplementary research and is awaiting registration application [5] - Differences between the loxoprofen sodium gel patch and the anti-inflammatory plaster include active ingredients, indications, and prescription attributes, with loxoprofen being a prescription drug for musculoskeletal pain [6]

Group 1: Company Overview and Strategy - The company focuses on mergers and acquisitions that align with its strategic development, aiming to enhance its supply chain, technology, market competitiveness, and product pipeline [2] - The company has established a comprehensive sales channel system, particularly in the outpatient market, which has become a new growth engine for performance [3] Group 2: Product Development and Market Potential - The company believes that the market for Loxoprofen Sodium Gel Patch in the outpatient sector has significant growth potential, supported by stable demand for topical patches in retail [4] - The company plans to continue investing in R&D to expand its product line and strengthen its brand "JiuYue" in the transdermal drug delivery field [3] Group 3: Competitive Positioning - Loxoprofen Sodium Gel Patch is a prescription drug effective for osteoarthritis and muscle pain, while the anti-inflammatory patch is an over-the-counter product with different ingredients and indications [5] - The company aims to leverage its complete supply chain to control costs and ensure product quality in response to competitive products gaining approval [2] Group 4: Financial Projections - For 2025, the company expects a revenue growth of 10-20% and a similar increase in net profit excluding non-recurring items [6] - The company warns that its operational plans and sales forecasts are subject to market conditions and other uncertainties, advising investors to remain aware of risks [7] Group 5: Marketing and Promotion Strategies - The company employs a multi-channel strategy for OTC promotion, integrating online and offline channels, and enhancing consumer experience through educational activities [7] - The brand "JiuYue" is positioned to meet diverse consumer needs through differentiated marketing and a varied product portfolio [7]

九典制药：招商证券、鹏扬基金等多家机构于3月25 日调研我司 证券之星消息，2025年3月25日九典制药（300705）发布公告称招商证券、鹏扬基金、圆信永丰基金 于2025年3月25日调研我司。 具体内容如下： 问：公司如何看待竞品获批对公司的影响？ 答：对于竞品获批公司将积极应对。在成本端，凭借完整的产业链布局，公司能够自主生产原料药和 关键辅料，确保产品质量的同时有效控制成本。在销售端，公司已建立起全渠道覆盖体系，特别是院外市 场，已成为业绩增长的新引擎，公司计划继续加大投入，以期在市场中占据更大份额。在研发端，公司始 终保持对研发的高投入，不断推陈出新，拓宽产品线。同时，公司将持续打造"久悦"贴膏品牌，通过先发 优势、渠道优势及成本优势等，致力于在经皮给药领域深化影响力，进一步稳固行业领先地位。 问：洛索洛芬钠凝胶贴膏在广东联盟集采的接续情况是怎样的？ 问：公司氟比洛芬凝胶贴膏预计何时获批？ 答：公司预计氟比洛芬凝胶贴膏将于今年底获批。 答：截至目前，洛索洛芬钠凝胶贴膏在广东联盟集采的接续工作尚处于报量阶段，采购文件暂未正式 发布。未来公司将持续关注广东联盟及全国集采相关动态，积极参与投标及接续工作。 ...